image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 3.28
-6.02 %
$ 7.87 M
Market Cap
-0.46
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one EKSO stock under the worst case scenario is HIDDEN Compared to the current market price of 3.28 USD, Ekso Bionics Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one EKSO stock under the base case scenario is HIDDEN Compared to the current market price of 3.28 USD, Ekso Bionics Holdings, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one EKSO stock under the best case scenario is HIDDEN Compared to the current market price of 3.28 USD, Ekso Bionics Holdings, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart EKSO

image
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.0$4.0$4.0$3.0$3.0$2.0$2.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
17.9 M REVENUE
-1.94%
-10.5 M OPERATING INCOME
30.78%
-11.3 M NET INCOME
25.45%
-9.85 M OPERATING CASH FLOW
18.32%
-37 K INVESTING CASH FLOW
76.43%
7.77 M FINANCING CASH FLOW
2132.47%
3.38 M REVENUE
-33.69%
-3.44 M OPERATING INCOME
-54.26%
-2.89 M NET INCOME
15.29%
-1.96 M OPERATING CASH FLOW
-37.12%
-10 K INVESTING CASH FLOW
52.38%
3.53 M FINANCING CASH FLOW
1223.89%
Balance Sheet Ekso Bionics Holdings, Inc.
image
Current Assets 18.8 M
Cash & Short-Term Investments 6.49 M
Receivables 7.24 M
Other Current Assets 5.11 M
Non-Current Assets 7.81 M
Long-Term Investments 0
PP&E 2.36 M
Other Non-Current Assets 5.44 M
24.36 %27.16 %19.18 %8.87 %20.43 %Total Assets$26.7m
Current Liabilities 7.54 M
Accounts Payable 1.55 M
Short-Term Debt 1.68 M
Other Current Liabilities 4.31 M
Non-Current Liabilities 6.41 M
Long-Term Debt 3.85 M
Other Non-Current Liabilities 2.55 M
11.13 %12.03 %30.89 %27.64 %18.31 %Total Liabilities$13.9m
EFFICIENCY
Earnings Waterfall Ekso Bionics Holdings, Inc.
image
Revenue 17.9 M
Cost Of Revenue 8.41 M
Gross Profit 9.51 M
Operating Expenses 20 M
Operating Income -10.5 M
Other Expenses 870 K
Net Income -11.3 M
20m20m15m15m10m10m5m5m00(5m)(5m)(10m)(10m)(15m)(15m)18m(8m)10m(20m)(10m)(870k)(11m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
53.06% GROSS MARGIN
53.06%
-58.35% OPERATING MARGIN
-58.35%
-63.21% NET MARGIN
-63.21%
-89.16% ROE
-89.16%
-42.51% ROA
-42.51%
-50.31% ROIC
-50.31%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Ekso Bionics Holdings, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -11.3 M
Depreciation & Amortization 1.61 M
Capital Expenditures 0
Stock-Based Compensation 1.63 M
Change in Working Capital 0
Others -1.75 M
Free Cash Flow -9.88 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Ekso Bionics Holdings, Inc.
image
Wall Street analysts predict an average 1-year price target for EKSO of $1.5 , with forecasts ranging from a low of $1 to a high of $2 .
EKSO Lowest Price Target Wall Street Target
1 USD -69.51%
EKSO Average Price Target Wall Street Target
1.5 USD -54.27%
EKSO Highest Price Target Wall Street Target
2 USD -39.02%
Price
Max Price Target
Min Price Target
Average Price Target
25252020151510105500Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 6
6. Ownership
Insider Ownership Ekso Bionics Holdings, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company announced its acceptance into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successfully demonstrated initial proof-of-concept in integrating artificial intelligence (“AI”)-enabled capabilities across its portfolio of Enterprise Health and Personal Health exoskeleton devices. globenewswire.com - 2 weeks ago
Ekso Bionics Announces New Effective Date of Reverse Stock Split SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. globenewswire.com - 1 month ago
Ekso Bionics Announces Reverse Stock Split SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split. globenewswire.com - 1 month ago
Ekso Bionics Accepted into NVIDIA Connect Program Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation globenewswire.com - 1 month ago
Ekso Bionics Holdings, Inc. (EKSO) Q1 2025 Earnings Call Transcript Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q1 2025 Earnings Conference Call May 5, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Ben Haynor - Lake Street Capital Markets Swayampakula Ramakanth - H.C. Wainwright Operator Greetings, and welcome to the Ekso Bionics First Quarter 2025 Financial Results Conference Call. seekingalpha.com - 2 months ago
Ekso Bionics (EKSO) Reports Q1 Loss, Misses Revenue Estimates Ekso Bionics (EKSO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.20 per share a year ago. zacks.com - 2 months ago
Ekso Bionics Reports First Quarter 2025 Financial Results SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. globenewswire.com - 2 months ago
Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. globenewswire.com - 2 months ago
Bionic P&O Chosen as First Distributor of Ekso Indego® Personal Within the Orthotics & Prosthetics Industry SAN RAFAEL, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has named Bionic Prosthetics & Orthotics Group LLC (“Bionic P&O”), a leading national provider of prosthetic and orthotic solutions, as a non-exclusive Ekso Indego® Personal device distributor. globenewswire.com - 2 months ago
Ekso Bionics Holdings, Inc. (EKSO) Q4 2024 Earnings Call Transcript Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Stephen Kilmer - IR Jerome Wong - Chief Financial Officer Scott Davis - Chief Executive Officer Conference Call Participants Li Chen - H.C. Wainwright Ben Haynor - Lake Street Capital Operator Greetings, and welcome to the Ekso Bionics Fourth Quarter 2024 Financial Results Conference Call. seekingalpha.com - 4 months ago
Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. globenewswire.com - 4 months ago
Ekso Bionics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3 – Conference Call to Follow SAN RAFAEL, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2024 after the close of trading on Monday, March 3, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. globenewswire.com - 4 months ago
8. Profile Summary

Ekso Bionics Holdings, Inc. EKSO

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 7.87 M
Dividend Yield 2.21%
Description Ekso Bionics Holdings, Inc. designs, develops, sells, and rents exoskeleton products in the Americas, Europe, the Middle east, Africa, the Asia Pacific, and internationally. The company operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods. It also provides EksoNR, a wearable bionic suit and rehabilitation device that assists physical therapists and physicians to treat patients with acquired brain injury, stroke, and spinal cord injury; and EksoUE is a wearable upper extremity assistive device that helps to reduce the effect of gravity on the wearer's shoulders and arms. Ekso Bionics Holdings, Inc. has a license agreement with Lockheed Martin Corporation. The company was incorporated in 2005 and is headquartered in Richmond, California.
Contact 1414 Harbour Way South, San Rafael, CA, 94804 https://www.eksobionics.com
IPO Date Jan. 17, 2014
Employees 61
Officers Mr. Jerome Wong Chief Financial Officer & Corporate Secretary Mr. Scott G. Davis Chief Executive Officer & Director Ms. Foon Lim Chwee President of APAC Ms. Katherine Strausser Principal Controls Engineer Mr. Jason C. Jones Chief Operating Officer Ms. Rachael Anderson Global Director of Marketing & Strategic Growth Mr. Stephan Aderhold Senior Vice President & GM of EMEA Ms. Ann Cookson Human Resources Director